The von Hippel–Lindau tumour suppressor gene: uncovering the expression of the pVHL172 isoform

• Published in: British journal of cancer Vol. 113; no. 2; pp. 336 - 344
• Main Authors: Chesnel, F, Hascoet, P, Gagné, J P, Couturier, A, Jouan, F, Poirier, G G, Le Goff, C, Vigneau, C, Danger, Y, Verite, F, Le Goff, X, Arlot-Bonnemains, Y
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 14.07.2015; Nature Publishing Group; Cancer Research UK
• Subjects: 692/420/2489/144/68; 692/699/1585/1588; 692/699/67/581; Amino Acid Sequence; Antibody Specificity; Biomedical and Life Sciences; Biomedicine; Blotting, Western; Cancer Research; Cell Line, Tumor; Drug Resistance; Epidemiology; Genes, Tumor Suppressor; Humans; Immunohistochemistry; Life Sciences; Molecular Diagnostics; Molecular Medicine; Molecular Sequence Data; Oncology; Protein Isoforms - analysis; Protein Isoforms - chemistry; Protein Isoforms - genetics; Von Hippel-Lindau Tumor Suppressor Protein - analysis; Von Hippel-Lindau Tumor Suppressor Protein - chemistry; Von Hippel-Lindau Tumor Suppressor Protein - genetics; kidney cancer; antibodies; ccRCC; VHL; protein isoforms
• ISSN: 0007-0920; 1532-1827
• DOI: 10.1038/bjc.2015.189

Background: The von Hippel–Lindau ( VHL ) gene encodes two mRNA variants. Variant 1 encodes two protein isoforms, pVHL 213 and pVHL 160 , that have been extensively documented in the literature. Variant 2 is produced by alternative splicing of exon 2 and encodes a pVHL isoform of 172 amino acids with a theoretical molecular weight of 19 kDa (pVHL 172 ), the expression of which has never been demonstrated so far due to the absence of suitable antibodies. Methods: We have generated an anti-pVHL monoclonal antibody (JD-1956) using pVHL172 recombinant protein. We tested the antibody against exogenous or endogenous expressed proteins in different cell lines. We identified the pVHL172 using a silencing RNA strategy. The epitope of the antibody was mapped using a peptide array. Results: We efficiently detected the three different isoforms of pVHL in cell lines and tumorigenic tissues by western blotting and immunohistochemistry and confirmed for the first time the endogenous expression of pVHL172. Conclusions: The endogenous expression of the three isoforms and particularly the pVHL172 has never been shown before due to a lack of a highly specific antibody since none of the available commercial antibodies distinguish the three isoforms of pVHL in cells or in both normal and cancerous human tissues. Evidence of pVHL172 expression emphasises the need to further study its implication in renal tumorigenesis and VHL disease.